

Transmembrane protein 121 as a novel inhibitor of cervical cancer metastasis

BOYU YANG^{1*}, YI CAI^{1*}, PING ZHU^{2,3*}, ZHIGANG JIANG¹, JIEYU AO¹, QING ZHANG¹, WUZHOYUAN¹, ZHILIN PENG¹, JIMEI CHEN², YAO WEN¹, YU CHEN², YUEQUN WANG¹, YAN SHI², XIAOLAN ZHU², XIANGLI YE¹, FANG LI¹, JIAN ZHUANG², XIUSHAN WU^{1,3}, YONGQING LI¹ and XIONGWEI FAN¹

¹State Key Laboratory of Developmental Biology of Freshwater Fish, College of Life Sciences, Hunan Normal University, Changsha, Hunan 410081; ²Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100; ³Guangdong Provincial Key Laboratory of Pathogenesis, Targeted Prevention and Treatment of Heart Disease, Guangzhou, Guangdong 510080, P.R. China

Received March 23, 2022; Accepted June 6, 2022

DOI: 10.3892/etm.2022.11509

Abstract. Transmembrane protein 121 (TMEM121) is isolated from the chicken heart using subtraction hybridisation. A previous study by the authors indicated that TMEM121 is highly expressed in adult mouse hearts and acts as an inhibitor of pathological cardiac hypertrophy. In the present study, the association between TMEM121 and cancer was investigated using bioinformatics tools, including Tumour Immune Estimation Resource (TIMER) 2.0, cBioPortal, LinkedOmics analysis, Kaplan-Meier plotter and UALCAN analysis. The expression, genetic variation, gene interaction network and co-expression pattern of *TMEM121* in tumours were analysed. The results revealed that *TMEM121* was expressed in various tumours and significantly downregulated in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) when compared with its expression in paracancerous tissues, whereas the methylation level of its promoter was increased in tumour tissues. Additionally, associations between TMEM121 and the PI3K/AKT signalling pathway, as well as the expression of cancer-related molecules, were detected. The aforementioned bioinformatics analysis suggests that TMEM121 may be involved in the development of cervical cancer. Therefore, gain-of-function and loss-of-function experiments in HeLa cells were conducted to verify the role of TMEM121 in cervical cancer. The assay using Cell Counting Kit-8 (CCK-8) revealed that the cell viability of HeLa cells

with TMEM121 overexpression was significantly reduced. High TMEM121 expression inhibited HeLa cell migration, as indicated by the decrease in the cell scratch healing rate. The western blot assay revealed that *TMEM121* overexpression downregulated the expression of B-cell lymphoma 2 (BCL-2), cyclin D1, cyclin E2 and phosphorylated (p)-AKT, while upregulating that of p27, E-cadherin and p-p38. When *TMEM121* was knocked down, retinoblastoma protein (RB), p53, p27, E-cadherin, p-JNK and p-p38 were inhibited, but cyclin E1 was promoted. By combining bioinformatics and experimental biology in the present study, the results demonstrated for the first time, to the best of our knowledge, that TMEM121 may be a novel inhibitor of cervical cancer that is linked to multiple signalling pathways, paving the way for the development of novel diagnostic and therapeutic strategies.

Introduction

Cervical cancer is one of the most prevalent malignant tumours and one of the most serious diseases threatening the health of women worldwide (1). According to the World Health Organization, there were an estimated 570,000 cases of cervical cancer and 311,000 deaths globally in 2018, making it the fourth most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths in women (2). Cervical cancer is caused by persistent human papillomavirus (HPV) infections, particularly HPV16 and HPV18 (3). Surgery, pharmaceutical treatment and radiotherapy are the currently available therapeutic options for cervical cancer; however, they are ineffective for treating advanced, metastatic, or recurrent tumours. Multiple factors contribute to the development and progression of cervical cancer. Therefore, the most promising strategy for the treatment of cervical cancer is to analyse the mechanism underlying cervical cancer development by identifying the relevant signal transduction processes and targeted molecular sites.

Transmembrane protein 121 (*TMEM121*) is a gene product isolated from the chicken heart via subtractive hybridisation (4). The human TMEM121 protein is a 319-amino acid,

Correspondence to: Professor Yongqing Li or Professor Xiongwei Fan, State Key Laboratory of Developmental Biology of Freshwater Fish, College of Life Sciences, Hunan Normal University, 36 Lushan Lu, Changsha, Hunan 410081, P.R. China
Email: liyongqing2002cn@aliyun.com
Email: fan_xiongwei@163.com

*Contributed equally

Key words: transmembrane protein 121, inhibitor, cervical cancer, cell migration, PI3K/AKT signaling pathway

six-transmembrane protein with a proline-rich C-terminal motif and an N-terminal extracellular signal-regulated kinase binding domain (D-domain) that is highly conserved in the evolution of different species (4,5). A previous study by the authors revealed that *TMEM121* is highly expressed in adult mouse hearts and acts as an inhibitor of pathologic cardiac hypertrophy (6). However, there have been few reports linking *TMEM121* to cancer. In the present study, it was determined that *TMEM121* may play a role in the development of cervical cancer.

Materials and methods

Tumour Immune Estimation Resource (TIMER) 2.0. The Tumour Immune Estimation Resource (TIMER; <http://timer.cistrome.org/>) is a comprehensive resource for the systematic analysis of immune infiltrates across various cancer types from The Cancer Genome Atlas (TCGA) database, with 10,897 samples from 32 cancer types (7). In the present study, the Gene_DE module was used to assess the differential expression of the *TMEM121* gene in tumours and adjacent normal tissues across all TCGA tumours. Statistical significance was calculated by Wilcoxon rank sum test.

cBioPortal. The cBioPortal for Cancer Genomics (<http://cbioportal.org/>) platform is a comprehensive web resource containing cancer genomics data from multiple platforms (8). The summary, plots and co-expression of cancer types were used to analyse the *TMEM121* gene expression in cancer.

LinkedOmics analysis. LinkedOmics is a publicly accessible portal that incorporates multi-omics and clinical data from the TCGA project for 32 cancer types and 11,158 patients (9). In this study, the LinkFinder tab of LinkedOmics was used to identify differentially expressed genes (DEGs) associated with *TMEM121*. The search and target datasets are derived from ribonucleic acid sequencing (RNA-SEQ). The results were statistically analysed using Pearson's and Spearman's correlation tests. The over-representation enrichment analysis and gene set enrichment analysis (GSEA) were completed using the LinkInterpreter tab.

Kaplan-Meier plotter. The Kaplan-Meier plotter (<http://kmplot.com/analysis>) can assess the impacts of 54K genes (mRNA, miRNA and protein) on survival in 21 cancer types. The database sources include Gene Expression Omnibus, European Genome-phenome Archive and TCGA. The main purpose of this tool is to identify and validate survival biomarkers based on a meta-analysis. The Kaplan-Meier plots were generated using the 'survplot' R package (<http://www.cbs.dtu.dk/~eklund/survplot/>) (10). Log rank testing was used to analyze statistical significance.

UALCAN analysis. UALCAN is an interactive web portal that performs in-depth analyses of TCGA gene expression data using TCGA level 3 RNA-seq and clinical data from 31 cancer types (11). In this study, UALCAN was used to analyse the relative *TMEM121* gene expression in normal as well as cervical squamous cell carcinoma and endocervical adenocarcinoma (CESE) tumour subgroups.

Cell cultures and transfection. HeLa cells were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% foetal bovine serum [Serana (WA) Pty, Ltd.] and incubated at 37°C and 5% CO₂. HeLa cells were transfected with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions, using 5 µg plasmid per dish. *TMEM121* overexpression was performed by inserting the CDS sequence of human *TMEM121* into pCMV-Tag2B (Agilent Technologies, Inc.) to prepare pCMV-Tag2B-*TMEM121*. *TMEM121*-specific shRNA sequence 5'-GATCCCCGCTTCTTCATCTCAGGAATTCTAGAGAATTCCTGAGATGAAGAAGCTTTTTC TCGA-3' was inserted into pSUPER (Oligoengine, Inc.) to produce pSUPER-*TMEM121* for *TMEM121* knockdown. Negative controls for *TMEM121* overexpression and knockdown were empty vectors of pCMV-Tag2B and pSUPER, respectively. The temperature conditions for transfection were the same as for cell culture for 6 h. Fresh medium was replaced 6 h after transfection. CCK-8 and cell scratch assays were performed 24 h after transfection, and western blotting was performed 48 h after transfection.

Western blotting. Total cellular proteins were extracted with RIPA lysis buffer (Elabscience Biotechnology, Inc.), and the protein amount was quantified by BCA assay. Protein (10-25 µl of each sample) was loaded on a 10% acrylamide gel. Electrophoresis was conducted at a constant pressure of 80 V until the target protein bands were separated. The protein was then transferred to a nitrocellulose (NC) filter membrane under a constant current of 300 mA. The NC membrane was immersed in Tris-buffered saline with 0.05% Tween-20 (TBST) containing 5% skim milk at room temperature for 1.5 h, and the excess milk was cleaned with TBST. The NC membrane was incubated at room temperature for 90 min with a primary antibody (diluted at a 1:1,000 by volume ratio), and then rinsed three times with TBST for 5 min each time. Subsequently, the NC membrane was incubated at room temperature for 90 min transferred with the secondary antibody (diluted at a 1:5,000 by volume ratio), and then rinsed with TBST three times for 5 min each time. Thereafter, a developing solution was dripped onto the membrane for imaging.

The anti-retinoblastoma (RB) (cat. no. 9313), anti-B-cell lymphoma 2 (BCL-2) (cat. no. 4223), anti-cleaved caspase-3 (cat. no. 9664), anti-cyclin D1 (cat. no. 2922), anti-cyclin E1 (cat. no. 20808), anti-cyclin E2 (cat. no. 4132), anti-light chain 3 α/β (LC3A/B) (cat. no. 4108), anti-phosphorylated c-Jun N-terminal kinase (p-JNK) (cat. no. 4668), anti-JNK (cat. no. 9252), anti-p-p38 (cat. no. 4511), anti-p38 (cat. no. 8690), anti-p-AKT (cat. no. 9271) and anti-AKT (cat. no. 9272) antibodies (all 1:1,000) were purchased from Cell Signaling Technology, Inc. The anti-p53 antibody was purchased from ProteinTech Group, Inc. (1:1,000; cat. no. 10442-1-AP), and the anti-E-cadherin antibody was purchased from Boster Biological Technology (1:1,000; cat. no. PB9561). GAPDH and α-tubulin were used as internal references, and antibodies against them were purchased from ProteinTech Group, Inc. (1:1,000; cat. nos. 60004-1-Ig and 66031-1-Ig, respectively). Goat anti-mouse IgG HRP-conjugated and goat anti-rabbit IgG HRP-conjugated secondary antibodies were purchased from CWBio (1:5,000; cat. nos. CW0102 and CW0103).




Figure 1. Expression of TMEM121 in various human tumours. The Gene_DE module revealed differential TMEM121 expression between tumour tissues and adjacent normal tissues across all TCGA tumours. Box plots were used to display gene expression level distribution. The red boxes represent tumour tissues, whereas the blue boxes represent normal tissues. The statistical significance calculated by the Wilcoxon rank-sum test is annotated by the number of asterisks. * $P<0.05$, ** $P<0.01$ and *** $P<0.001$. TMEM121, transmembrane protein 121; TCGA, The Cancer Genome Atlas.




Figure 2. Relative TMEM121 expression in normal and different subgroups of CESC tissues. (A) Sample types, (B) individual cancer stages, (C) age of patients, (D) tumour grade, (E) nodal metastatic status, and (F) weight of patients. * $P<0.05$ and *** $P<0.001$. TMEM121, transmembrane protein 121; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma.

Cell Counting Kit-8 (CCK-8) assay. The cell viability assays were performed using Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology). In brief, 20 μ l CCK-8 reagent was applied per well at 24, 48 and 72 h following plasmid vector transfection, and the cells were incubated at 37°C for 1 h in a humidified CO₂ incubator. The optical density of the medium was then measured as an absorbance at a wavelength of 450 nm on a microplate reader (Bio-Rad Laboratories, Inc.).

Cell scratch assay. Transfected cells were seeded on 6-well plates and incubated to almost 100% confluence. A pipette tip perpendicular to the cell plane was used to scratch the cell monolayer to create scratches. After the scratches were completed, the cells were incubated in 37°C 5% CO₂ with serum-free medium (using the same reagents as aforementioned). Confluence on either side of the wound at the start of the assay. The cells in the culture plate were observed under an inverted microscope and images were captured at 0, 24, 48 and




Figure 3. Methylation levels of the *TMEM121* gene promoter in normal and various CESC subgroups. (A) Sample type, (B) individual cancer stages, (C) age of patients; (D) weight of patients, (E) tumour grade, and (F) nodal metastatic status. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$. *TMEM121*, transmembrane protein 121; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma.

72 h. ImageJ 1.53c software (National Institutes of Health) was then used for cell scratch area analysis. The scratch healing rate was calculated according to the scratch area: (Original scratch area - scratch area at a certain time) / original scratch area $\times 100$.

Statistical analysis. Graphpad Prism 8.0 software (GraphPad Software, Inc.) was used for statistical analysis. Data are expressed as the mean \pm SD. The unpaired t-test was used to evaluate the differences between two groups. Wilcoxon rank-sum test was used in TIMER 2.0. $P < 0.05$ was used to indicate a statistically significant difference. Each experiment was repeated at least three times. Log rank testing was used to analyze survival curve significance. Pearson's and Spearman's correlation tests were used in LinkedOmics analysis.

Results

***TMEM121* expression in tumours.** TIMER was used to analyse and compare *TMEM121* expression in various human tumour tissues with that in normal tissues. As shown in Fig. 1, *TMEM121* expression was significantly downregulated in CESC, kidney chromophobe, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, and uterine corpus endometrial carcinoma compared with that in normal tissues.

Subsequently, UALCAN was used to categorise CESC samples derived from TCGA database based on sample type, cancer stage, weight, age, tumour grade and lymph node metastatic status in order to analyse the *TMEM121* expression among various categories. The results revealed that the *TMEM121* expression in the various CESC subgroups was lower than that in normal tissues (Fig. 2). Furthermore, the methylation levels of the *TMEM121* gene promoter were




Figure 4. Prognostic value of *TMEM121* expression in the overall survival of patients with CESC by the Kaplan-Meier plotter. Survival curves were plotted for high (red) and low (black) expression groups. *TMEM121*, transmembrane protein 121; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma.

higher in cancerous tissues in various categories than those in normal tissues (Fig. 3).

Association between *TMEM121* expression and survival in patients with CESC. The Kaplan-Meier plotter was used to investigate the prognostic significance of *TMEM121* expression in patients with CESC. The survival analysis revealed




Figure 5. *TMEM121*-related DEGs (LinkedOmics). (A) Pearson's correlation coefficient was used for the correlation of *TMEM121*-related DEGs in CESC. (B) Heat maps of positively correlated significant genes with *TMEM121* in CESC. (C) Heat maps of negatively correlated significant genes with *TMEM121* in the CESC. *TMEM121*, transmembrane protein 121; DEGs, differentially expressed genes; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma.

that there was no significant difference in the overall survival between the low and high *TMEM121* expression groups of patients with CESC ($P=0.87$) (Fig. 4).

DEGs associated with *TMEM121*. In CESC, DEGs associated with *TMEM121* were identified using LinkedOmics and displayed in heat maps (12). As illustrated in the volcano plot (Fig. 5A), a total of 19,904 DEGs were identified, with the top 50 significantly expressed, either positively or negatively, and the related genes are displayed in heat maps (Fig. 5B and C).

Functional enrichment analysis of *TMEM121*. Next, the GSEA LinkInterpreter module was used for Gene Ontology analysis to categorise *TMEM121*-related DEGs into three categories based on their molecular functions, biological processes they contribute to, and cellular locations where they occur (13). In the biological process category, the *TMEM121*-related DEGs were primarily enriched in 'monoamine transport', 'nicotinamide adenine dinucleotide/hydrogen dehydrogenase (NADH) complex assembly', 'microvillus organisation', and

'cargo loading into the vesicle' (Fig. 6A-a). In the category of cellular components, they were primarily enriched in the 'extracellular matrix', 'ribosome', 'endoplasmic reticulum exit site' and promyelocytic leukaemia (PML) body' (Fig. 6A-b). Furthermore, they were primarily involved in molecular functions such as 'structural constituent of ribosome', 'extracellular matrix structural constituent', 'ubiquitinyl hydrolase activity' and 'cysteine-type peptidase activity' (Fig. 6A-c).

Further analysis revealed the possible functional pathways involved in the development and progression of CESC, which include the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway ('ribosome', 'oxidative phosphorylation', 'glycosaminoglycan biosynthesis' and nucleotide-binding and oligomerisation domain (NOD)-like receptor signalling pathway'; Fig. 6B-a), the PANTHER pathway ('JAK/STAT signalling pathway', 'phosphatidylinositol 3 (PI3)-kinase pathway', 'Toll receptor signalling pathway' and platelet-derived growth factor (PDGF) signalling pathway'; Fig. 6B-b), and the WikiPathway ('cytoplasmic ribosomal proteins', 'oxidative phosphorylation', 'epidermal growth factor/epidermal growth factor receptor (EGF/EGFR)




Figure 6. Gene Set Enrichment Analysis of the *TMEM121* in CESC. (A-a) Biological process, (A-b) cellular components, and (A-c) molecular functions. (B-a) KEGG pathway, (B-b) PANTHER pathway, and (B-c) Wiki pathway. Blue bars represent positive correlations, and orange bars represent negative correlations. *TMEM121*, transmembrane protein 121; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; KEGG, Kyoto Encyclopaedia of Genes and Genomes.

signalling pathway’, and the transforming growth factor ‘(TGF)-beta signalling pathway’; Fig. 6B-c). Therefore, the occurrence and progression of CESC involve aberrant changes in multiple signalling pathways.

TMEM121 is associated with the *PI3K/AKT* signalling pathway. To further identify *TMEM121* as a putative cancer regulator, the *PI3K/AKT* signalling pathway was investigated. In CESC, the cBioPortal platform was used to correlate *TMEM121* expression levels with mutations of key molecules of the *PI3K/AKT* signalling pathway, such as caspase-3 (CASP3) and cadherin-1 (CDH1). Ultimately, PIK3CB, AKT1, CASP3 and CDH1 were identified to be significantly correlated to *TMEM121* expression in CESC (Fig. 7). Pearson's correlation coefficient analysis revealed that the expression level of *TMEM121* was positively correlated with the expression level of AKT1 and negatively correlated with the expression levels of PIK3CB, CASP3 and CDH1. These results suggest that *TMEM121* influences cancer progression via the *PI3K/AKT* signalling pathway and is closely associated to cell migration and apoptosis.

Validation of TMEM121 overexpression and knockdown in the HeLa cell line. The overexpression and knockdown experiments were used to explore the role of *TMEM121* in cervical cancer cells. The treated plasmids, pCMV-Tag2B, pCMV-Tag2B-*TMEM121*, pSUPER and pSUPER-*TMEM121*, were transfected into the HeLa cell lines for overexpression and RNA interference. The total proteins were extracted for western blot analysis. As pCMV-Tag2B-*TMEM121* and pSUPER-*TMEM121* were transfected into the HeLa cells, the *TMEM121* protein expression level significantly increased or decreased when compared to the empty vector groups (Fig. 8).

TMEM121 overexpression inhibits cell proliferation in the CCK-8 assay. To elucidate the role of *TMEM121* in the pathogenesis of CESC, the CCK-8 assay was used to measure the proliferative capacity of HeLa cells following *TMEM121* overexpression or knockdown. The CCK-8 assay measures cell viability and can be used to assess cell proliferation. The results revealed that HeLa cells with *TMEM121* overexpression showed significantly reduced cell viability at 24, 48 and 72 h when compared with the empty vector control group,




Figure 7. Correlation between the mRNA expression level of *TMEM121* and that of other genes in CESC samples (cBioPortal). (A) *TMEM121* vs. PI3KCD, (B) *TMEM121* vs. AKT1, (C) *TMEM121* vs. CASP3, and (D) *TMEM121* vs. CDH1. *TMEM121*, transmembrane protein 121; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; PI3KCD, phosphatidylinositol 3-kinase catalytic subunit delta; caspase-3, CASP3; CDH1, cadherin-1.

indicating that cell proliferation was inhibited (Fig. 9A). By contrast, there was no significant difference between the *TMEM121*-knockdown group and the control group (Fig. 9B).

TMEM121 inhibits cervical cancer cell migration in a cell scratch assay. A cell scratch experiment was also conducted to assess cell migration through the wound closure rate of the HeLa cells transfected with *TMEM121*-overexpression and *TMEM121*-knockdown (Fig. 10A). The wound closure rates were measured at 24, 48 and 72 h after the scratch, and significant differences were found when compared with the empty vector groups. The results revealed that the migratory ability of HeLa cells with *TMEM121* overexpression significantly decreased at 24 and 48 h (Fig. 10B), whereas there was no significant change in the migratory ability of HeLa cells with knocked down *TMEM121* expression (Fig. 10C).

Overexpression and knockdown of TMEM121 regulate cancer-related factors in CESC. To verify the impact of *TMEM121* overexpression and knockdown on CESC progression at the protein expression level, western blotting

was conducted to assess markers associated with cancer cell proliferation and apoptosis (Fig. 11A). The quantitative results revealed that when *TMEM121* was overexpressed in HeLa cells, the protein expression levels of BCL-2, cyclin D1, and cyclin E2 significantly decreased, whereas those of p27 significantly increased (Fig. 11B). *TMEM121* knockdown significantly inhibited RB, p53 and p27 protein expression, and promoted the expression of cyclin E1. In addition, neither treatment had a significant effect on cleaved caspase-3 protein expression (Fig. 11B).

Subsequently, the expression levels of proteins related to cancer cell migration and autophagy were determined (Fig. 12A), and the results revealed that the expression level of E-cadherin significantly increased when *TMEM121* was overexpressed, indicating that cell migration was inhibited, which was consistent with the results of the cell migration scratch assay (Fig. 12B). When the expression of *TMEM121* was decreased, the expression of E-cadherin was downregulated (Fig. 12B), even though there was no significant change in cell migration. However, when *TMEM121* was overexpressed or inhibited, LC3, a marker of autophagy, was not significantly altered (Fig. 12B).




Figure 8. Identification of TMEM121 overexpression and knockdown. (A) TMEM121 western blotting results of HeLa cells transfected with pCMV-Tag2B, pCMV-Tag2B-TMEM121, pSUPER and pSUPER-TMEM121. (B) Quantitative analysis of western blot results (n=3). *P<0.05. TMEM121, transmembrane protein 121.

In addition, the phosphorylation levels of several key factors in cancer-related signalling pathways were estimated. The results revealed that when *TMEM121* was overexpressed, P38 phosphorylation was promoted, whereas AKT phosphorylation was inhibited. When *TMEM121* was knocked down, the expression of both p-P38 and p-JNK was decreased (Fig. 12C).

Discussion

The identification of new regulatory factors and novel mechanisms underlying cervical cancer development and metastasis is crucial to develop more effective cancer diagnostics and treatment. A previous study by the authors revealed that the *TMEM121* gene is highly expressed in the adult heart and may inhibit cardiac hypertrophy (6). However, it has not




Figure 9. HeLa cell viability determined by CCK-8 assay at 24, 48 and 72 h after transfection. (A) CCK-8 results in the HeLa cells with *TMEM121* overexpression. (B) CCK-8 results in the HeLa cells with *TMEM121* knockdown (n=4). **P<0.01. CCK-8, Cell Counting Kit-8; *TMEM121*, transmembrane protein 121.

been reported whether *TMEM121* is implicated in cancer development.

The present study is the first, to the best of our knowledge, to focus on the association between *TMEM121* and cancer. Bioinformatics analysis revealed that *TMEM121* expression was significantly downregulated in human cervical cancer tissues compared with that in normal tissues in various classification groups. As an epigenetic phenomenon, aberrant gene silencing in cancer cells has been linked to CpG island hypermethylation of DNA in gene promoter regions (14-16). Abnormally high methylation levels of *TMEM121* gene promoter were detected in a number of CESC subgroups, suggesting that the epigenetic downregulation of *TMEM121* may contribute to CESC development. Notably, in the bioinformatics analysis, it was determined that the survival curves of patients with high expression of *TMEM121* were not significantly different. *TMEM121* is a transmembrane protein (5), so we speculate that it receives and transmits signals on the




Figure 10. Cell scratch assay used to assess the effect of *TMEM121* overexpression and knockdown on HeLa cell migration at 24, 48 and 72 h after scratching. (A) The ImageJ tool was used to delineate the scratch boundary of HeLa cells with *TMEM121* overexpression and knockdown 24, 48 and 72 h after the scratch. (B) The scratch area of the *TMEM121*-overexpression group was measured, and the scratch healing rate was calculated. The comparison between the experimental and control groups is illustrated using a bar chart. (C) The scratch area of the *TMEM121*-knockdown group was measured, and the scratch healing rate was calculated. The comparison between the experimental and control groups is illustrated using a bar chart (n=3). *P<0.05 and **P<0.01. *TMEM121*, transmembrane protein 121.

cell membrane to regulate intracellular cancer development. Therefore, it is hypothesised that the mutation of *TMEM121* will affect the early stage of cervical cancer, and will affect the occurrence and metastasis of tumour cells. The mutation




Figure 11. Western blot detection of tumour cell proliferation and apoptosis markers. (A) Western blot results of RB, p53, BCL-2, cleaved caspase-3, p27, cyclin D1, cyclin E1, cyclin E2 and β -tubulin. (B) Quantitative analysis of the western blot results (n=3). *P<0.05 and **P<0.01. RB, retinoblastoma protein; BCL-2, B-cell lymphoma 2; *TMEM121*, transmembrane protein 121.

of *TMEM121* will assist cervical cancer metastasis. A limitation of this study is the lack of significant differences in the survival curves of patients with high and low *TMEM121* expression. This may be due to the insufficient number of patients with cervical cancer included in the TCGA database or as the differential expression of this gene is not sufficient to be significantly reflected in the survival rate. Furthermore, *TMEM121* has been linked to PI3K/AKT signalling as well as other cancer-related factors. Genetic events leading to the aberrant activation of the PI3K/AKT pathway are one of the most common drivers of human cancer (17). These results suggest that *TMEM121* is involved in CESC regulation. Cell function analysis revealed that *TMEM121* overexpression reduced not only the migratory ability of cervical cancer cells




Figure 12. Western blot detection of tumour cell proliferation and apoptosis markers. (A) Western blot results of E-cadherin, LC3A/B, p-JNK, JNK, p-p38, p38, p-AKT, AKT and GAPDH. (B) Quantitative analysis of western blot results of p-JNK, p-p38 and p-AKT (n=3). (C) Quantitative analysis of the western blot results of E-cadherin and LC3 (n=3). *P<0.05, **P<0.01 and ***P<0.001. LC3A/B light chain 3 α/β ; p-, phosphorylated; JNK, c-Jun N-terminal kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

but also their proliferation ability. However, the reverse was not evident in the HeLa cell lines with *TMEM121* knockdown. These findings suggest that *TMEM121* can inhibit cervical cancer cell migration and proliferation but is not required for either of these processes to occur.

The *RB* gene is the first discovered tumour suppressor gene. The RB protein binds to various cellular proteins during the G0 and G1 phases, such as the E2F family and ELF-1, and inhibits their activated transcription function, thereby blocking the G1 phase and preventing S-phase entry (18). Therefore, RB is considered an important checkpoint in controlling cell proliferation (19). p27 belongs to the Cip/Kip family of cyclin-dependent kinase inhibitors (20). As an important recently discovered tumour suppressor gene, the reduction of p27 protein expression level is closely related to the development, progression, and prognosis of malignancies (21,22). When *TMEM121* expression was knocked down, RB and p27 expression was downregulated, which may predict increased cancer risk or progression. The cell cycle progression in mammalian cells from the G1 to S phases is driven by cyclins D-type (including cyclin D1) and E-type (including cyclins E1 and E2) (23,24). In contrast to RB and p27, when *TMEM121* was overexpressed, the protein expression levels of cyclin D1 and cyclin E2 decreased, and cells were prevented from entering the S phase, inhibiting cell proliferation. Conversely,

when *TMEM121* is knocked down, an increase in cyclin E2 protein may promote cell proliferative activity, although this increase does not seem to be apparent.

LC3A and LC3B are autophagosome markers (25), and their expression was not altered by *TMEM121* overexpression or knockdown. E-cadherin expression has been linked to tumour metastasis. As a key molecule mediating the intercellular adhesion, E-cadherin acts as the 'glue' between cells and a marker for cell migration (26). When E-cadherin expression is upregulated, cell migration is inhibited. The internal molecular mechanism underlying E-cadherin upregulation may be attributed to a reduction in AKT phosphorylation following *TMEM121* overexpression. Previous research has revealed that inhibiting the PI3K/AKT signalling pathway by decreasing the p-AKT expression can effectively prevent cancer cell migration (27,28). It is hypothesised that endogenous *TMEM121* inhibits cervical cancer cell migration via downregulation of p-AKT. The mechanism by which *TMEM121* inhibits p-AKT activation is not well understood. Nevertheless, the structural characteristics of *TMEM121* suggest that it interacts with kinases on the membrane and disrupts the kinase signal transmission. Upstream of the AKT signal activation, there is a protein-protein interaction on the membrane; however, it is unknown whether *TMEM121* is involved in this interaction. This should be verified in future experiments.

The present study mainly focused on the identification of novel candidate genes regulating carcinogenesis through bioinformatics and experiments for preliminary verification of its functions. In fact, previous laboratory work has demonstrated the function of TMEM121 in colorectal cancer cells, gastric cancer cells, liver cancer HepG2 cells, lung cancer A549 cells and cervical cancer HeLa cells, but it was found that TMEM121 only played a role in HeLa cells. Therefore, it can only be confirmed that TMEM121 is involved in the regulation of cervical cancer. However, the HeLa cell line was only used throughout the study. Considering the heterogeneity of different cell lines even within the same type of cancer, and the complexity of further molecular mechanism studies, in the future, further validation with the use of other cell lines will be performed. TMEM121 is a triple transmembrane protein. Questions as to how it sorts the signals on the membrane for cancer cells, and how it affects the phosphorylation of AKT through a protein interaction mechanism will be addressed in a follow-up study.

In conclusion, the results of the present study demonstrated for the first time, to the best of our knowledge, that TMEM121 may be a novel inhibitor of cervical cancer migration that is linked to multiple signalling pathways. The present study offers unique theoretical insights into the development of cervical cancer and the pursuit of novel diagnostic and interventional approaches.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81670290, 81801392, 32071175, 31572349, 81370230, 81570279, 81974019 and 81600320), the National Key Research and Development Program of China (grant nos. 2018YFA0108700 and 2017YFA0105602), the NSFC Projects of International Cooperation and Exchanges (grant no. 81720102004), The Research Team Project of Natural Science Foundation of Guangdong Province of China (grant no. 2017A030312007), the Science and Technology Planning Project of Guangdong Province (grant no. 2022B1212010010), the Key Program of Guangzhou Science Research Plan (grant no. 201904020047), The Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (grant nos. DFJH201812, KJ012019119 and KJ012019423) and the Hunan Provincial Natural Science Foundation of China (grant no. 2020JJ5354).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XF, YL, XW and PZ made significant contributions to the conception or design of the study. YWa, ZJ, QZ, ZP, JC, YWe, YS, XZ, XY, JZ, WY, YCh and FL performed experiments.

BY, YCa and JA were responsible for the acquisition, analysis or interpretation of the data and drafted this work. BY and YCa confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Liu Y, Zhu H, Mo L, Xu R, Li X, Li T, Zhao L, Ren Y, Ou R and Xu Y: Flt3L and GM-CSF enhance anti-tumor effect of HPV16/18 vaccine via increasing immune response. *Am J Transl Res* 12: 6027-6042, 2020.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424, 2018.
- Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M and Franceschi S: Global burden of human papillomavirus and related diseases. *Vaccine* 5: F12-F23, 2012.
- Neset AL and Bader DM: Hole is a novel gene product expressed in the developing heart and brain. *Mech Dev* 117: 347-350, 2002.
- Zhou J, Li Y, Liang P, Yuan W, Ye X, Zhu C, Cheng Y, Wang Y, Li G, Wu X and Liu M: A novel six-transmembrane protein hHole functions as a suppressor in MAPK signaling pathways. *Biochem Biophys Res Commun* 333: 344-352, 2005.
- Xu W, Wang Y, Zhou J, Zhu X, Zhang S, Yuan W, Liu X, Shi Y, Cao L, Zeng Q, *et al*: Cardiac specific overexpression of hHole attenuates isoproterenol-induced hypertrophic remodeling through inhibition of extracellular signal-regulated kinases (ERKs) signalling. *Curr Mol Med* 16: 515-523, 2016.
- Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Res* 77: e108-e110, 2017.
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, *et al*: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 6: pii, 2013.
- Vasaikar SV, Straub P, Wang J and Zhang B: LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res* 46: D956-D963, 2017.
- Nagy Á, Munkácsy G and Gyórfy B: Pancancer survival analysis of cancer hallmark genes. *Sci Rep* 11: 6047, 2021.
- Chandrashekar DS, Bashel B, Balasubramanya SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. *Neoplasia* 19: 649-658, 2017.
- Gu Z, Eils R and Schlesner M: Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* 32: 2847-2849, 2016.
- Gene Ontology Consortium: Going forward. *Nucleic Acids Res* 43: D1049-D1056, 2015.
- Esteller M: CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. *Oncogene* 21: 5427-5440, 2002.
- Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 349: 2042-2054, 2003.
- Ushijima T and Asada K: Aberrant DNA methylation in contrast with mutations. *Cancer Sci* 101: 300-305, 2010.
- Hoxhaj G and Manning BD: The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. *Nat Rev Cancer* 20: 74-88, 2020.

18. Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. *Genes Dev* 7: 331-342, 1993.
19. Knudsen ES and Knudsen KE: Tailoring to RB: Tumour suppressor status and therapeutic response. *Nat Rev Cancer* 8: 714-724, 2008.
20. Pérez-Luna M, Aguasca M, Perearnau A, Serratosa J, Martínez-Balbas M, Pujol MJ and Bachs O: PCAF regulates the stability of the transcriptional regulator and cyclin-dependent kinase inhibitor p27 Kip1. *Nucleic Acids Res* 40: 6520-6533, 2012.
21. Perearnau A, Orlando S, Islam A, Gallastegui E, Martínez J, Jordan A, Bigas A, Aligué R, Pujol MJ and Bachs O: p27Kip1, PCAF and PAX5 cooperate in the transcriptional regulation of specific target genes. *Nucleic Acids Res* 45: 5086-5099, 2017.
22. Roilo M, Kullmann MK and Hengst L: Cold-inducible RNA-binding protein (CIRP) induces translation of the cell-cycle inhibitor p27Kip1. *Nucleic Acids Res* 46: 3198-3210, 2018.
23. Liu L, Michowski W, Inuzuka H, Shimizu K, Nihira NT, Chick JM, Li N, Geng Y, Meng AY, Ordureau A, *et al*: G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. *Nat Cell Biol* 19: 177-188, 2017.
24. Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, *et al*: Cell-cycle-targeting micrnas as therapeutic tools against refractory cancers. *Cancer Cell* 31: 576-590.e8, 2017.
25. Wu J, Dang Y, Su W, Liu C, Ma H, Shan Y, Pei Y, Wan B, Guo J and Yu L: Molecular cloning and characterization of rat LC3A and LC3B-two novel markers of autophagosome. *Biochem Biophys Res Commun* 339: 437-442, 2006.
26. Bruner HC and Derksen PWB: Loss of e-cadherin-dependent cell-cell adhesion and the development and progression of cancer. *Cold Spring Harb Perspect Biol* 10: a029330, 2018.
27. Wang D, Yang T, Liu J, Liu Y, Xing N, He J, Yang J and Ai Y: Propofol inhibits the migration and invasion of glioma cells by blocking the PI3K/AKT pathway through miR-206/ROCK1 axis. *Onco Targets Ther* 13: 361-370, 2020.
28. Sheng XY, Wang CH, Wang CF and Xu HY: Long-chain non-coding SOX21-AS1 promotes proliferation and migration of breast cancer cells through the PI3K/AKT signaling pathway. *Cancer Manag Res* 12: 11005-11014, 2020.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.